Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial
Authors:
- Milagros González-RiveraMGMilagros González-Rivera
- Miriam LoboMLMiriam Lobo
- Sara López-TarruellaSLSara López-Tarruella
- Yolanda JerezYJYolanda Jerez
- María del Monte-MillánMMMaría del Monte-Millán
- Tatiana MassarrahTMTatiana Massarrah
- Rocío Ramos-MedinaRRRocío Ramos-Medina
- Inmaculada OcañaIOInmaculada Ocaña
- Antoni PicornellAPAntoni Picornell
- Sonia Santillán GarzónSGSonia Santillán Garzón
- Lucía Pérez-CarborneroLPLucía Pérez-Carbornero
- José A. García-SaenzJGJosé A. García-Saenz
- 15 April 2016
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 156 (3) , 507-515
Abstract
We describe the status and frequency of germline DNA genetic findings in an unselected prospective cohort of triple negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Study population includes 124 consecutive patients with stage II-III TNBC from a trial exploring the antitumor activity of neoadjuvant carboplatin/docetaxel chemotherapy enrolled between 2012 and March 2015, to determine the frequency of germline DNA genetic mutations. 17.1 % of the patients with germline DNA tested had deleterious mutations in any of the analyzed genes (12.38 % in BRCA1, 1.9 % in BRCA2 and BARD1 and 0.95 % in RAD51D). Attending the intrinsic subtype, all the BRCA1/2 carriers tested had basal-like subtype. Among wild-type (WT) patients, 70.11 % had basal subtype, 16.09 % HER2 enriched, 1.15 % Luminal B, and 4.60 % Normal-like. Mean age at diagnosis was significantly lower in mutation-carriers compared with no carriers (43.72 vs 53.10, p = 0.004). 3 BRCA1/2 carriers were detected between 51 and 60 years, and only one deleterious mutation (BARD1) over 60 years. A positive familiar history of breast and ovarian cancer was more frequent in patients with deleterious mutations (39.39 vs 17.94 %, p = 0.043). Our study confirms the prevalence of BRCA1/2 mutations in TNBC patients. TNBC should therefore be considered by itself as a criterion for BRCA1/2 genetic testing. Determination of other breast cancer predisposition genes implicated in homologous recombination should also be discussed in this population. However, no definitive conclusions can be reached due to the low prevalence and the uncertain clinical impact of most of the genes included.Keywords
Funding Information
- Fundación Salud 2000 (ES)-Fundación SEOM
- Roche Farma S.A.
This publication has 40 references indexed in Scilit:
- Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patientsGenetics in Medicine, 2014
- Breast-Cancer Risk in Families with Mutations in PALB2New England Journal of Medicine, 2014
- In Brief: BRCA1 and BRCA2The Journal of Pathology, 2013
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007
- Meta-Analysis of BRCA1 and BRCA2 PenetranceJournal of Clinical Oncology, 2007
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast CancerJNCI: Journal of the National Cancer Institute, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003